Levels of serum anti-NMDAR antibodies in patients with first-episode schizophrenia
Abstract：Objective To explore serum level of anti-NMDAR antibodies in patients with first-episode schizophrenia .Methods The serum concentrations of anti -NMDAR antibodies in 80 healthy controls and 82 patients with first -episode schizophrenia were assessed by enzyme linked immunosor‐bent assay (ELISA) .Results The level of serum anti-NMDAR antibody in first-episode schizophreni‐a was observably higher than healthy controls[(208 .84 ± 113 .60)pg/ml vs(107 .29 ± 40 .57) pg/ml] , and the difference was statistically significant (t = - 7 .162 ,P < 0 .01) .The difference of serum anti-NMDAR antibody concentrations between men(215 .75 ± 133 .20)pg/ml and women(200 .00 ± 83 .14)pg/ml in patients with schizophrenia was no statistically significant (t= 0 .621 ,P> 0 .05) .The serum concentra‐tion of anti -NMDAR antibodies was positively correlated with PANSS total score ,the positive syn‐drome scores and the negative syndrome scores (r= 0 .364 ,0 .276 ,0 .260 ,respectively ;P< 0 .05) .Con‐clusions The level of serum antibody anti -NMDAR in first -episode schizophrenia is increased ,and there is a positive correlation with the clinical symptoms of schizophrenia .
Keywords：SchizophreniaGlutamic acidNMDA receptorAnti-NMDAR antibody
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 328-331 )